ANN ARBOR, Mich., Oct. 5, 2011 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative
medicines for serious central nervous system diseases, announced
today that James S. Kuo, M.D.,
M.B.A., the Company's Chief Executive Officer and Chairman, will
provide a brief update on its Alzheimer's program at the NYC
Medtech Forum. Adeona will be one of four featured companies at the
invitation-only event on Tuesday evening, October 11, 2011, at the offices of Kaye Scholer, LLP in New York City.
"We are thrilled to invite Dr. Kuo back to the NYC Medtech Forum
following his presentation on Adeona's CNS clinical development
programs last December," said John R.
Lieberman, CPA, Managing Director at Perelson Weiner, LLP.
"Our exclusive forum offers a unique platform for companies in the
life science sector to share the potential of their clinical
programs and product candidates with our select invited
guests."
About NYC Medtech
NYC Medtech is a professional platform that assists many
different collaborators in the life science, biotech, device and
pharma industries have successful outcomes. This unique program not
only brings together companies and investors but all people that
are involved from reporters, scientists, academia, trade
organizations, international partners, etc. The NYC Medtech program
introduces invited participants with relevant timely introductions
whether through the website, email or the personal touch at the NYC
Medtech Forum. The NYC Medtech initiative was created and founded
by John R. Lieberman at Perelson
Weiner, LLP, along with Wendy Brown
of Merrill Lynch and Ted King of
SaddleRock Advisors. For more information about NYC Medtech, please
visit the website at www.nycmedtech.com.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing
innovative medicines for the treatment of serious central nervous
system diseases. The Company's strategy is to license product
candidates that have demonstrated a certain level of clinical
efficacy and develop them to a stage that results in a significant
commercial collaboration. Adeona is developing, or has partnered
the development of, drug product candidates to treat multiple
sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and
Alzheimer's disease. The Company is currently preparing to make the
following products commercially available: reaZin™, a
prescription medical food for the dietary management of zinc
deficiency associated with Alzheimer's disease, and
wellZin™, a homeopathic over-the-counter medicine for
reducing the duration and symptoms of the common cold. Adeona also
operates Adeona Clinical Laboratory, a wholly owned clinical
reference laboratory that provides a broad array of chemistry and
microbiology diagnostic tests. For more information, please visit
Adeona's website at www.adeonapharma.com.
SOURCE Adeona Pharmaceuticals, Inc.